A linear polyethylenimine mediated siRNA-based therapy targeting human epidermal growth factor receptor in SPC-A1 xenograft mice

详细信息    查看全文

• 作者：Pinghai Zhang (1)
  Nuo Xu (1)
  Lei Zhou (1)
  Xin Xu (1)
  Yuehong Wang (1)
  Ka Li (1)
  Zhaochong Zeng (2)
  Xiangdong Wang (1)
  Xin Zhang (1)
  Chunxue Bai (1)
  
• 关键词：RNA interference ; Small interfering RNA ; Epidermal growth factor receptor ; Linear ; polyethylenimine ; Non small cell lung cancer ; Intraperitoneal injection
• 刊名：Translational Respiratory Medicine
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：1
• 期：1
• 全文大小：1400KB
• 参考文献：1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. / CA Cancer J Clin 2010, 60:277-00. CrossRef
  2. Carney DN: Lung cancer–time to move on from chemotherapy. / N Engl J Med 2002, 346:126-28. CrossRef
  3. Azzoli CG, Temin S, Giaccone G: 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. / J Oncol Pract 2012, 8:63-6. CrossRef
  4. Baldotto CS, Cronemberger EH, De Biasi P, Zamboni M, Sousa A, Zukin M, Small IA, Ferreira CG: Palliative care in poor-performance status small cell lung cancer patients: is there a mandatory role for chemotherapy? / Support Care Cancer 2012, 20:2721-727. CrossRef
  5. Booth CM, Shepherd FA, Peng Y, Darling G, Li G, Kong W, Mackillop WJ: Adjuvant chemotherapy for non-small cell lung cancer: practice patterns and outcomes in the general population of Ontario, Canada. / J Thorac Oncol 2012, 7:559-66. CrossRef
  6. Ray M, Salgia R, Vokes EE: The role of EGFR inhibition in the treatment of non-small cell lung cancer. / Oncologist 2009, 14:1116-130. CrossRef
  7. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, / et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. / N Engl J Med 2009, 361:947-57. CrossRef
  8. Xu N, Zhang X, Wang X, Ge HY, Wang XY, Garfield D, Yang P, Song YL, Bai CX: FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cells. / Acta Pharmacol Sin 2012, 33:675-81. CrossRef
  9. Engelman JA, Janne PA: Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. / Clin Cancer Res 2008, 14:2895-899. CrossRef
  10. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, / et al.: Detection of mutations in EGFR in circulating lung-cancer cells. / N Engl J Med 2008, 359:366-77. CrossRef
  11. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, / et al.: PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. / Cancer Res 2007, 67:11924-1932. CrossRef
  12. Sharma SV, Bell DW, Settleman J, Haber DA: Epidermal growth factor receptor mutations in lung cancer. / Nat Rev Cancer 2007, 7:169-81. CrossRef
  13. Burris HA 3rd: Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. / Oncogene 2009,28(Suppl 1):S4-S13. CrossRef
  14. Edelstein ML, Abedi MR, Wixon J: Gene therapy clinical trials worldwide to 2007–an update. / J Gene Med 2007, 9:833-42. CrossRef
  15. Pirollo KF, Chang EH: Targeted delivery of small interfering RNA: approaching effective cancer therapies. / Cancer Res 2008, 68:1247-250. CrossRef
  16. Lewis DL, Wolff JA: Delivery of siRNA and siRNA expression constructs to adult mammals by hydrodynamic intravascular injection. / Methods Enzymol 2005, 392:336-50. CrossRef
  17. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. / Nature 2001, 411:494-98. CrossRef
  18. Kumsta C, Hansen M: C. elegans rrf-1 Mutations Maintain RNAi Efficiency in the Soma in Addition to the Germline. / PLoS One 2012, 7:e35428. CrossRef
  19. Liu Q, Muruve DA: Molecular basis of the inflammatory response to adenovirus vectors. / Gene Ther 2003, 10:935-40. CrossRef
  20. Lungwitz U, Breunig M, Blunk T, Gopferich A: Polyethylenimine-based non-viral gene delivery systems. / Eur J Pharm Biopharm 2005, 60:247-66. CrossRef
  21. Yuan JJ, Jin RH: Approaches to nanostructure control and functionalizations of polymer@silica hybrid nanograss generated by biomimetic silica mineralization on a self-assembled polyamine layer. / Beilstein J Nanotechnol 2011, 2:760-73. CrossRef
  22. Hassani Z, Francois JC, Alfama G, Dubois GM, Paris M, Giovannangeli C, Demeneix BA: A hybrid CMV-H1 construct improves efficiency of PEI-delivered shRNA in the mouse brain. / Nucleic Acids Res 2007, 35:e65. CrossRef
  23. Liao HW, Yau KW: In vivo gene delivery in the retina using polyethylenimine. / Biotechniques 2007, 42:285-86. CrossRef
  24. Ohana P, Schachter P, Ayesh B, Mizrahi A, Birman T, Schneider T, Matouk I, Ayesh S, Kuppen PJ, de Groot N, / et al.: Regulatory sequences of H19 and IGF2 genes in DNA-based therapy of colorectal rat liver metastases. / J Gene Med 2005, 7:366-74. CrossRef
  25. Wirth M, Fritsche P, Stojanovic N, Brandl M, Jaeckel S, Schmid RM, Saur D, Schneider G: A simple and cost-effective method to transfect small interfering RNAs into pancreatic cancer cell lines using polyethylenimine. / Pancreas 2011, 40:144-50. CrossRef
  26. Sidi AA, Ohana P, Benjamin S, Shalev M, Ransom JH, Lamm D, Hochberg A, Leibovitch I: Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin. / J Urol 2008, 180:2379-383. CrossRef
  27. Grzelinski M, Urban-Klein B, Martens T, Lamszus K, Bakowsky U, Hobel S, Czubayko F, Aigner A: RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. / Hum Gene Ther 2006, 17:751-66. CrossRef
  28. Akinc A, Thomas M, Klibanov AM, Langer R: Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. / J Gene Med 2005, 7:657-63. CrossRef
  29. Zhang M, Zhang X, Bai CX, Chen J, Wei MQ: Inhibition of epidermal growth factor receptor expression by RNA interference in A549 cells. / Acta Pharmacol Sin 2004, 25:61-7.
  30. Xu XM, Chen Y, Chen J, Yang S, Gao F, Underhill CB, Creswell K, Zhang L: A peptide with three hyaluronan binding motifs inhibits tumor growth and induces apoptosis. / Cancer Res 2003, 63:5685-690.
  31. Bai L, Zhu R, Chen Z, Gao L, Zhang X, Wang X, Bai C: Potential role of short hairpin RNA targeting epidermal growth factor receptor in growth and sensitivity to drugs of human lung adenocarcinoma cells. / Biochem Pharmacol 2006, 71:1265-271. CrossRef
  32. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I: Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. / Nat Biotechnol 2005, 23:457-62. CrossRef
  33. Castanotto D, Rossi JJ: The promises and pitfalls of RNA-interference-based therapeutics. / Nature 2009, 457:426-33. CrossRef
  34. Billiet L, Gomez JP, Berchel M, Jaffres PA, Le Gall T, Montier T, Bertrand E, Cheradame H, Guegan P, Mevel M, / et al.: Gene transfer by chemical vectors, and endocytosis routes of polyplexes, lipoplexes and lipopolyplexes in a myoblast cell line. / Biomaterials 2012, 33:2980-990. CrossRef
  35. Hobel S, Aigner A: Polyethylenimine (PEI)/siRNA-mediated gene knockdown in vitro and in vivo. / Methods Mol Biol 2010, 623:283-97. CrossRef
  36. Endres T, Zheng M, Beck-Broichsitter M, Samsonova O, Debus H, Kissel T: Optimising the self-assembly of siRNA loaded PEG-PCL-lPEI nano-carriers employing different preparation techniques. / J Control Release 2012, 160:583-91. CrossRef
  37. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A: RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. / Gene Ther 2005, 12:461-66. CrossRef
  38. Wang M, Tucker JD, Lu P, Wu B, Cloer C, Lu Q: Tris[2-(acryloyloxy)ethyl]isocyanurate cross-linked low-molecular-weight polyethylenimine as gene delivery carriers in cell culture and dystrophic mdx mice. / Bioconjug Chem 2012, 23:837-45. CrossRef
  39. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, / et al.: Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. / Nat Med 2005, 11:263-70. CrossRef
  40. Bonnet ME, Erbacher P, Bolcato-Bellemin AL: Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response. / Pharm Res 2008, 25:2972-982. CrossRef
  41. Zamora MR, Budev M, Rolfe M, Gottlieb J, Humar A, Devincenzo J, Vaishnaw A, Cehelsky J, Albert G, Nochur S, / et al.: RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. / Am J Respir Crit Care Med 2011, 183:531-38. CrossRef
  42. Davis ME: The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. / Mol Pharm 2009, 6:659-68. CrossRef
  43. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A: Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. / Nature 2010, 464:1067-070. CrossRef
  
• 作者单位：Pinghai Zhang (1)
  Nuo Xu (1)
  Lei Zhou (1)
  Xin Xu (1)
  Yuehong Wang (1)
  Ka Li (1)
  Zhaochong Zeng (2)
  Xiangdong Wang (1)
  Xin Zhang (1)
  Chunxue Bai (1)
  
  1. Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, 20032, China
  2. Department of Radiotherapy, Zhongshan Hospital, Fudan University, Shanghai, 20032, China
  
• ISSN：2213-0802

文摘

Background Linear polyethylenimine (LPEI) is considered as a desirable gene in vivo delivery system, but whether it could deliver the specific siRNA targeted EGFR to the tumor site to inhibit the growth of NSCLC xenograft in nude mice still needs to be examined. Methods In this study, LPEI/siRNA was made into a complex and SPC-A1-xenografted mice model was established. Then, stable LPEI/siRNA-EGFR complexes were intraperitoneally administrated. Afterwards, tumor growth was measured every 3 days. At the end of the experiment, tumor volume was calculated, and tumors were weighed, and examined for EGFR expression, proliferation, and apoptosis evaluations. By using blood samples, toxicity tests including aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea and creatinine (Cr) were measured for liver and renal function evaluation. Serum concentrations of TNF-α and IFN-γ were also examined. Results Our results demonstrated that LPEI/siRNA-EGFR complexes could downregulate EGFR expression in SPC-A1 xenografted tumor upon single i.p. injection. LPEI/siRNA-EGFR complexes inhibited tumor growth and did not induce organ toxicity in SPC-A1-xenografted mice. At the end of the experiment no significant IFN-α increase was detected in LPEI/siRNA complexes or glucose-treated groups. Conclusions The novel modality of siRNA-based therapy targeting EGFR may be of great potential in NSCLC treatment.